Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Stealth Biotherapeutics Corp ADR (MITO)

Stealth Biotherapeutics Corp ADR (MITO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire - Wed Nov 16, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire - Tue Nov 1, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq : MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire - Fri Oct 7, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery,...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Announces Departure of Chief Financial Officer PR Newswire - Fri Sep 30, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events PR Newswire - Thu Sep 15, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ PR Newswire - Mon Jul 11, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal PR Newswire - Mon Jun 27, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal PR Newswire - Mon Jun 27, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome PR Newswire - Tue Jun 14, 2022

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization...

MITO : 0.3200 (-1.36%)
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA PR Newswire - Wed Oct 20, 2021

/PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

MITO : 0.3200 (-1.36%)

Barchart Exclusives

3 Dividend Kings With Unstoppable Dividend Growth Potential Barchart - 42 minutes ago
Discover three quality companies with healthy financials, low dividend payout ratios, and a history of incredible dividend growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot